Successful treatment with micafungin of invasive pulmonary aspergillosis in acute myeloid leukemia, with renal failure due to amphotericin B therapy

T Yokote; T Akioka; S Oka; T Fujisaka; T Yamano; S Hara; M Tsuji; T Hanafusa

doi:10.1007/s00277-003-0736-8

Successful treatment with micafungin of invasive pulmonary aspergillosis in acute myeloid leukemia, with renal failure due to amphotericin B therapy

Ann Hematol. 2004 Jan;83(1):64-6. doi: 10.1007/s00277-003-0736-8. Epub 2003 Aug 28.

Authors

T Yokote¹, T Akioka, S Oka, T Fujisaka, T Yamano, S Hara, M Tsuji, T Hanafusa

Affiliation

¹ Department of First Internal Medicine, Osaka Medical College, 2-39-7 Daigakumachi, Takatsuki City, Osaka, Japan. [email protected]

PMID: 14661114
DOI: 10.1007/s00277-003-0736-8

Abstract

Invasive aspergillosis is an important factor in the morbidity and mortality of patients suffering from hematologic disorders treated with chemotherapy. Treatment with amphotericin B is often limited because of toxicity, particularly nephrotoxicity. We describe a case of invasive pulmonary Aspergillus fumigatus infection in acute myeloid leukemia with renal failure due to amphotericin B therapy, which responded to treatment with a new antifungal agent, micafungin. Micafungin appears to be an effective and safe therapy for Aspergillus infections with renal failure due to amphotericin B.

Publication types

Case Reports

MeSH terms

Amphotericin B / adverse effects*
Aspergillosis / diagnosis
Aspergillosis / drug therapy*
Aspergillosis / etiology
Echinocandins
Humans
Leukemia, Monocytic, Acute / microbiology*
Lipopeptides
Lipoproteins / therapeutic use*
Lung Diseases, Fungal / diagnosis
Lung Diseases, Fungal / drug therapy*
Lung Diseases, Fungal / etiology
Male
Micafungin
Middle Aged
Peptides, Cyclic / therapeutic use*
Renal Insufficiency / chemically induced*
Renal Insufficiency / microbiology
Treatment Outcome

Substances

Echinocandins
Lipopeptides
Lipoproteins
Peptides, Cyclic
Amphotericin B
Micafungin